BMN 111
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Dec 12, 2017 → Jun 1, 2031
NCT ID
NCT03424018About BMN 111
BMN 111 is a phase 3 stage product being developed by BioMarin Pharmaceutical for Achondroplasia. The current trial status is active. This product is registered under clinical trial identifier NCT03424018. Target conditions include Achondroplasia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03424018 | Phase 3 | Active |
| NCT02724228 | Phase 2 | Active |
| NCT02055157 | Phase 2 | Completed |
Competing Products
20 competing products in Achondroplasia